ARISING HEALTHALIVE. AWAKE. AWARE.Read the magazines →

← November 19, 2026 edited reader edition

THE ARISING · Longevity & Healthspan

An experimental blood marker distinguished a precursor to ovarian cancer

A study using known tissue diagnoses found a strong signal. That is not a validated screening test.

A blood marker separated people with a known fallopian tube precursor lesion from those with normal tissue or benign growths in a research comparison.

The work, published in Nature Medicine by Wilhelm and colleagues, is a peer-reviewed study in people. The researchers measured an RNA molecule called Tu-stroma in blood serum from 506 individuals. The groups were 143 with histologically normal adnexa (the ovaries and fallopian tubes), 88 with benign growths in that area, 43 with the precursor lesion on its own, and 232 with high-grade serous carcinoma.

High-grade serous carcinoma is the most common type of epithelial ovarian cancer and the leading cause of ovarian-cancer deaths, according to the paper. It arises from a lesion called serous tubal intraepithelial carcinoma, or STIC. STIC has not spread into surrounding tissue. It is typically identified only when a pathologist examines fallopian tube tissue after it has been removed.

Tu-stroma is a long noncoding RNA, a type of RNA that does not make a protein. It travels in extracellular vesicles, tiny packets that cells release into the blood. Here the question was whether measuring this RNA distinguished people whose tissue already had a known diagnosis.

Levels of Tu-stroma in vesicles were higher in women with STIC and in those with high-grade serous carcinoma than in controls and in women with benign growths. This held in premenopausal women too, a group of 211 within the larger cohort.

The researchers compared the RNA with CA125, the protein marker most often used in ovarian cancer testing. They used a measure called area under the curve, where 1.0 is a perfect test and 0.5 is no better than chance. For STIC versus controls, Tu-stroma scored 0.99 and CA125 scored 0.59. For STIC versus benign growths, the scores were 0.99 and 0.31.

For high-grade serous cancer, the gap was narrower. Tu-stroma scored 0.99 against controls, compared with 0.96 for CA125. Against benign growths, it scored 0.98 against 0.84.

The RNA also showed no systematic rise in 116 samples from people with inflammatory or physiologic conditions, or in 160 samples from people with cancers outside the ovary. Each group was compared with 100 healthy controls. The authors say this supports specificity to the ovarian disease setting.

The authors also modeled higher-risk groups to estimate predictive values, rather than measuring those values through a real screening program. They call Tu-stroma a candidate marker linked to pre-invasive and early disease. They note that prospective testing in consecutively enrolled, real-world cohorts is required to confirm how well it performs and whether it is clinically useful.

An excellent score for telling apart known groups does not tell us how many positive tests would be false alarms in a population where the lesion is rare. A prospective study must also show whether an alert leads to care that does more good than harm.

Sources

THE ARISING NEWSLETTER

Science moves forward.
Come with it.

Research, clear explanations, and a little room for wonder.
Read and follow The Arising on Substack.

Find The Arising on Substack ↗